98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12072-025-10893-5 | DOI Listing |
Clin Lung Cancer
August 2025
Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hepatol Int
August 2025
The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning, China.
Hepatol Int
July 2025
Department of Intensive Care Unit, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), No. 54 Post Road, Shangcheng District, Hangzhou, 310000, Zhejiang, China.
Hepatol Int
July 2025
The First Affiliated Hospital, Zhejiang Chinese Medical University, Post and Telecom Road 54, Shangcheng District, Hangzhou City, 310007, Zhejiang Province, People's Republic of China.
Hepatol Int
July 2025
Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), D-1, Vasant Kunj, New Delhi, 110 070, India.
Background And Aims: Large-volume paracentesis (LVP), a therapeutic procedure for cirrhosis patients with refractory ascites, is associated with paracentesis-induced circulatory dysfunction (PICD). While albumin infusion is known to prevent PICD, it is unknown whether the addition of vasoconstrictors to albumin reduces complications of LVP.
Methods: Cirrhosis patients undergoing LVP for refractory ascites were randomized to receive albumin alone (Gr.